Literature DB >> 33059982

Effect of COVID-19-associated lockdown on the metabolic control of patients with type 2 diabetes.

Ourania Psoma1, Eleftheria Papachristoforou2, Aikaterini Kountouri3, Kostantinos Balampanis3, Athena Stergiou3, Vaia Lambadiari3, Stavros Liatis2, Vasilis Tsimihodimos4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33059982      PMCID: PMC7540191          DOI: 10.1016/j.jdiacomp.2020.107756

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


× No keyword cloud information.
Dear editor Previous studies have shown that disasters usually have detrimental effects on the metabolic control of patients with chronic conditions. Coronavirus disease-19 (COVID-19) represents an epidemic that results from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since no vaccine or effective treatments for the disease have been developed, most countries used the measure of lockdown to limit the transmission of the disease The duration of total lockdown in Greece was 42 days. The aim of our study was to prospectively access the effect of the COVID-19-associated lockdown on the metabolic control of patients with type 2 diabetes. For this reason, we compared the post-lockdown values of various metabolic indices with those of the most recent visit before lockdown in 380 consecutive patients with type 2 diabetes. Researchers were not involved in the arrangement of patients' appointments which were set centrally by an electronic system. The measurement of all anthropometric and laboratory parameters was performed at the outpatient clinics for all patients. The age of patients was 62.5 ± 11.9 years and 62% were males. The median time between the two visits was 18 weeks (range 8–30 weeks). Surprisingly, we found that HbA1c, body mass index (BMI) and total cholesterol values decreased during the lockdown, while those of the other metabolic indices remained constant (Table 1 ). These beneficial effect on glycemia were unrelated to baseline HbA1c concentration or BMI and was not affected by baseline glucose-lowering treatment except for sulfonylureas. Patients receiving sulfonylureas before lockdown (n = 16) exhibited a non-significant increase in HbA1c (from 7.18 ± 0.57 to 7.43 ± 0.87).
Table 1

Effect of lockdown on metabolic control in patients with type 2 diabetes.

Before lockdownAfter lockdownP
BMI (Kg/m2)30.6 ± 5.830.3 ± 5.60.01
Systolic blood pressure (mmHg)138 ± 19137 ± 16NS
Systolic blood pressure (mmHg)80 ± 1282 ± 46NS
Heart rate (bpm)75 ± 1375 ± 11NS
Glucose (mg/dl)127 ± 42123 ± 35NS
HbA1c (%)6.9 ± 1.36.7 ± 0.90.015
Total Cholesterol (mg/dl)160 ± 35154 ± 350.04
Triglycerides (mg/dl)138 ± 74132 ± 67NS
HDL-Cholesterol (mg/dl)49 ± 1349 ± 13NS
LDL-Cholesterol (mg/dl)82 ± 2980 ± 30NS
Aspartate aminotransferase (IU/l)20 ± 920 ± 9NS
Alanine aminotransferase (IU/l)23 ± 1422 ± 13NS
Gamma-glutamyltransferase (IU/l)23 ± 1222 ± 12NS

NS: non-significant.

Effect of lockdown on metabolic control in patients with type 2 diabetes. NS: non-significant. The rather unexpected findings could be attributed to several reasons. Patients who had a labor-consuming work schedule pre-lockdown had now the opportunity to work from their home. The latter led to a better eating behavior (home-prepared meals which are better than take-aways at the office), a chance for more exercise (the 30-minute daily time allowed could be better than nothing since heavily working patients had now some more time for themselves). Additionally, none of our patients was personally affected by COVID-19 infection and likely many of them were not affected indirectly either (aside from the need to lockdown) and thus the physical and emotional stress were low. In conclusion, we found that during lockdown most patients with type 2 diabetes exhibited a small but significant improvement in glycemia, body weight and total cholesterol while the other metabolic parameters remained stable.
  6 in total

1.  Effect of the COVID-19 Pandemic Lockdown on the Management of Diabetic Retinopathy: A Cross-Sectional Study.

Authors:  Vaishali Prajapati; Krishna Shah; Dhruvi Shah; Mayur B Wanjari; Deepika Singhal
Journal:  Cureus       Date:  2022-08-02

2.  [Impact of the alteration of the continuity of care in diabetes type 2 patients during the COVID-19 pandemic].

Authors:  F J Cuevas Fernández; J C Gutiérrez Galeote; M R García Marrero; M J Iglesias Girón; A Cabrera de León; A Aguirre-Jaime
Journal:  Semergen       Date:  2022-03-22

Review 3.  The Spill-Over Impact of the Novel Coronavirus-19 Pandemic on Medical Care and Disease Outcomes in Non-communicable Diseases: A Narrative Review.

Authors:  Ivy Lynn Mak; Eric Yuk Fai Wan; Teenie Kwan Tung Wong; Wendy Woo Jung Lee; Esther Wai Yin Chan; Edmond Pui Hang Choi; Celine Sze Ling Chui; Mary Sau Man Ip; Wallace Chak Sing Lau; Kui Kai Lau; Shing Fung Lee; Ian Chi Kei Wong; Esther Yee Tak Yu; Cindy Lo Kuen Lam
Journal:  Public Health Rev       Date:  2022-04-27

4.  Effect of COVID-19 lockdown on Moroccan patients with type 1 and type 2 diabetes.

Authors:  Rochdi Kaddar; Chayma Tarik; Maryam Atmani; Ikrame Enakhil; Nada Fakhri; Mohamed Khalis; Abdellah Lotfy; Nadia El Kadmiri
Journal:  Bull Natl Res Cent       Date:  2022-05-16

5.  The impact of lockdown caused by the COVID-19 pandemic on glycemic control in patients with diabetes.

Authors:  Edyta Sutkowska; Dominik M Marciniak; Karolina Sutkowska; Karolina Biernat; Justyna Mazurek; Natalia Kuciel
Journal:  Endocrine       Date:  2022-01-24       Impact factor: 3.925

6.  Effect of COVID-19-Associated Lockdown on Patients With Diabetic Retinopathy.

Authors:  Irini Chatziralli; Eleni Dimitriou; Dimitrios Kazantzis; Genovefa Machairoudia; Georgios Theodossiadis; Panagiotis Theodossiadis
Journal:  Cureus       Date:  2021-05-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.